Insight Molecular Diagnostics Inc. SEC filings IMDX
Insight Molecular Diagnostics Inc. has 688 filings in SEC EDGAR's recent list, going back to May 14, 2015. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 21, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Jul 24, 2026 | — |
| 424B5 | Prospectus supplement | Feb 11, 2026 | — |
| S-8 | Employee stock plan registration | Aug 18, 2025 | — |
| 424B3 | Prospectus | Apr 8, 2025 | — |
| S-1 | Registration statement | Mar 28, 2025 | — |
| 424B5 | Prospectus supplement | Feb 10, 2025 | — |
| 424B3 | Prospectus | Oct 22, 2024 | — |
| S-3/A | Filing | Oct 18, 2024 | — |
| S-3 | Shelf registration | Oct 16, 2024 | — |
| 424B5 | Prospectus supplement | Aug 9, 2024 | — |
| S-3 | Shelf registration | Aug 1, 2024 | — |
| 424B3 | Prospectus | Jun 4, 2024 | — |
| 424B3 | Prospectus | May 23, 2024 | — |
| S-3/A | Filing | May 17, 2024 | — |
| S-3 | Shelf registration | May 10, 2024 | — |
| 424B5 | Prospectus supplement | Apr 6, 2023 | — |
| 424B5 | Prospectus supplement | Apr 18, 2022 | — |
| 424B5 | Prospectus supplement | Apr 15, 2022 | — |
| 424B5 | Prospectus supplement | Apr 13, 2022 | — |
| 424B3 | Prospectus | Jul 29, 2021 | — |
| S-3 | Shelf registration | Jul 14, 2021 | — |
| S-8 | Employee stock plan registration | Jul 7, 2021 | — |
| 424B5 | Prospectus supplement | Jun 14, 2021 | — |
| S-3 | Shelf registration | May 28, 2021 | — |
| 424B5 | Prospectus supplement | Feb 8, 2021 | — |
| S-3MEF | Filing | Feb 5, 2021 | — |
| 424B5 | Prospectus supplement | Feb 4, 2021 | — |
| 424B5 | Prospectus supplement | Jan 21, 2021 | — |
| S-3 | Shelf registration | Jul 30, 2020 | — |
| 424B5 | Prospectus supplement | Apr 27, 2020 | — |
| 424B5 | Prospectus supplement | Mar 20, 2020 | — |
| 424B5 | Prospectus supplement | Jan 6, 2020 | — |
| 424B5 | Prospectus supplement | Nov 14, 2019 | — |
| S-8 | Employee stock plan registration | Jul 23, 2019 | — |
| S-3 | Shelf registration | Jun 6, 2019 | — |
| 424B5 | Prospectus supplement | Feb 11, 2019 | — |
| 424B5 | Prospectus supplement | Feb 8, 2019 | — |
| 424B5 | Prospectus supplement | Feb 7, 2019 | — |
| S-8 | Employee stock plan registration | Aug 30, 2018 | — |
| 424B5 | Prospectus supplement | Jul 27, 2018 | — |
| S-3 | Shelf registration | Oct 2, 2017 | — |
| S-8 | Employee stock plan registration | Jun 30, 2017 | — |
| 424B3 | Prospectus | Nov 16, 2016 | — |
| S-1/A | Amended registration statement | Oct 19, 2016 | — |
| S-1/A | Amended registration statement | Oct 18, 2016 | — |
| S-1 | Registration statement | Sep 26, 2016 | — |
| S-8 | Employee stock plan registration | Jan 11, 2016 | — |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- IMDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Nashville, TN
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1642380
- Former names
- OncoCyte Corp (until Jun 17, 2025); Oncocyte Corp (until Jun 17, 2025)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.